Mohammed Z H Farooqui
Overview
Explore the profile of Mohammed Z H Farooqui including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
2085
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baskar S, Peng H, Gaglione E, Carstens E, Lindorfer M, Ahn I, et al.
Blood
. 2025 Jan;
PMID: 39774793
Monoclonal antibodies (mAbs) improve survival of patients with mature B-cell malignancies. Fcγ-receptor dependent effector mechanisms kill tumor cells but can promote antigen loss through trogocytosis, contributing to treatment failures. Cell-bound...
2.
Huntington S, Cheng W, Sarpong E, Leng S, Farooqui M, Agu U, et al.
Leuk Lymphoma
. 2024 May;
65(7):932-942.
PMID: 38696747
With increasing focus on novel targeted therapies for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), this longitudinal claims-based study evaluated real-world CLL/SLL treatment sequences, particularly sequential targeted therapy. Among patients with...
3.
Woyach J, Stephens D, Flinn I, Bhat S, Savage R, Chai F, et al.
Cancer Discov
. 2023 Nov;
14(1):66-75.
PMID: 37930156
Significance: This first-in-human phase I study demonstrates the safety and preliminary efficacy of nemtabrutinib in patients with relapsed/refractory B-cell malignancies. These data support further exploration of nemtabrutinib in larger clinical...
4.
Andre T, Shiu K, Kim T, Jensen B, Jensen L, Punt C, et al.
N Engl J Med
. 2020 Dec;
383(23):2207-2218.
PMID: 33264544
Background: Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) tumors after previous therapy. The efficacy of PD-1 blockade as compared with chemotherapy as first-line...
5.
Liao J, Farooqui M, Marinello P, Hartzel J, Anderson K, Ma J, et al.
Contemp Clin Trials
. 2020 Oct;
99:106179.
PMID: 33086159
The phase III, randomized, active-controlled, multicenter, open-label KEYNOTE-183 study (NCT02576977) evaluating pomalidomide and low dose dexamethasone (standard-of-care [SOC]) with or without pembrolizumab in patients with refractory or relapsed and refractory...
6.
Sun C, Nierman P, Kendall E, Cheung J, Gulrajani M, Herman S, et al.
Blood
. 2020 Mar;
136(1):93-105.
PMID: 32202637
Inhibition of the B-cell receptor pathway, and specifically of Bruton tyrosine kinase (BTK), is a leading therapeutic strategy in B-cell malignancies, including chronic lymphocytic leukemia (CLL). Target occupancy is a...
7.
Usmani S, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin R, et al.
Lancet Haematol
. 2019 Jul;
6(9):e448-e458.
PMID: 31327689
Background: Lenalidomide and dexamethasone has been a standard of care in transplant-ineligible patients with newly diagnosed multiple myeloma. The addition of a third drug to the combination is likely to...
8.
Mateos M, Orlowski R, Ocio E, Rodriguez-Otero P, Reece D, Moreau P, et al.
Br J Haematol
. 2019 May;
186(5):e117-e121.
PMID: 31090915
No abstract available.
9.
Ribrag V, Avigan D, Green D, Wise-Draper T, Posada J, Vij R, et al.
Br J Haematol
. 2019 Apr;
186(3):e41-e44.
PMID: 30937889
No abstract available.
10.
Ahn I, Farooqui M, Tian X, Valdez J, Sun C, Soto S, et al.
Blood
. 2018 Feb;
131(21):2357-2366.
PMID: 29483101
The safety and efficacy of ibrutinib (420 mg) in chronic lymphocytic leukemia (CLL) were evaluated in a phase 2 study; 51 patients had aberration (TP53 cohort) and 35 were enrolled...